The authors emphasize that “switching” any TPO-RA to avatrombopag is probably the best possible therapeutic alternative for switching in ITP, especially when a response has not been achieved with the first TPO-RA used [36]. Here, TPO is linked to autoimmune thrombocytopenic purpura.